Otsuka Aims for Abilify Maintena’s 30% Share in LAI Antipsychotic Market

Otsuka Holdings President Tatsuo Higuchi Otsuka Holdings hopes to see Abilify Maintena (aripiprazole), a once-monthly injectable version of Abilify, quickly snatch up 30% of the long-acting injectable (LAI) antipsychotic market in the world, President Tatsuo Higuchi said at an earnings...read more